Readystate Asset Management LP Gilead Sciences, Inc. Call Options Transaction History

Readystate Asset Management LP

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $4.42 Million - $5.58 Million	66,400 New	66,400 $5.57 Billion
Q1 2024 May 10, 2024	SELL	$71.58 - $87.29 $1.58 Million - $1.93 Million	-22,100 Reduced 51.76%	20,600 $1.51 Billion
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $2.91 Million - $3.3 Million	39,700 Added 1323.33%	42,700 $3.46 Billion
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $76,010 - $86,700	-1,000 Reduced 25.0%	3,000 $231 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $309,240 - $352,320	4,000 New	4,000 $332 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Readystate Asset Management LP, based on Form 13F filings with the SEC.

Stay updated on Readystate Asset Management LP with notifications on news.